Pivotal Life Sciences Secures bioVenture Partners Fund II, at $389m. Fund II will continue Pivotal bioVenture Partners’ core strategy of investing in companies based in North America and Europe developing innovative and impactful therapeutics.
Read also – Turkey-based Getir Completes Acquisition of FreshDirect
Additionally, the establishment of Fund II will enable Pivotal to continue to attract talented leaders to guide and grow these companies in key healthcare and therapeutic areas.
Rob Hopfner, Managing General Partner said, “We believe in the power of outstanding teams and excellent execution. The ongoing dislocation in the markets is creating opportunities to match the best entrepreneurs and drug developers with the most promising therapeutic innovation, a strategy that we are well positioned to execute, Pivotal Life Sciences. We see great opportunities to create value by leveraging the reach of our team’s unique and broad talent network, together with a proven ability to pick winners through different market cycles.”
Pivotal bioVenture Partners invests in companies at all stages from seed stage to publicly listed, with a preference for leading or co-leading investments and working alongside
entrepreneurs as company builders and active board members.
Read also – Webster Financial Corporation Acquire Ametros Financial Corp
Pivotal bioVenture Partners invests both in established companies developing transformative medicines, such as Karuna and Vaxcyte, and in entirely new companies by providing seed funding and support in company building.
In all of its investments, the goal of Pivotal bioVenture Partners is to be a committed partner supporting its portfolio companies throughout their evolution, including in late-stage private rounds, IPOs, and follow-on rounds in the public market.
Read also – CA-based Distributional Secures $11m in Seed Funding
Peter Bisgaard, Managing Director, Pivotal Life Sciences said, “We see this moment as a time of great opportunity in which our team’s historic focus on therapeutics with transformative potential in disease management matches where the biotech market has evolved over the past few years. It’s inspiring to see that technologies that emerged in recent years are now translating into development programs with a line of sight to patient impact, which is at the core of our focus,”.
The Pivotal bioVenture Partners team will leverage the full capabilities of Pivotal Life Sciences’ global investment group, which invests through private, public, and other creative financing vehicles in the general life sciences field.
Read also – Kansas-based Regenerative Farming Company Greenfield Robotics Secures Investment Chipotle Mexican Grill
Pivotal bioVenture Partners will build upon the Firm’s commitment to and relationships with groundbreaking academic scientists, including those supported by their philanthropic academic grant program directly funding academic investigators research.
Pivotal bioVenture Partners operates under the broader Pivotal Life Sciences group, a life sciences asset management platform focused on investing in therapeutic innovation worldwide, across asset classes and spanning all stages of company development, with over $2 billion under management.
Read also – California-based Nitricity Secures Investment from Chipotle Mexican Grill
About Pivotal bioVenture Partners
Established in 2017, Pivotal bioVenture Partners is a venture capital partnership dedicated to investing in innovative companies developing therapeutics to address major unmet medical needs and improving patient lives.The name “Pivotal” reflects both the group’s focus on medicines that have the potential to transform patient lives, as well as their determination to be a valued partner for their portfolio companies.
Read also – Chicago-based Aether Fuels Secures US$8.5m in Pre-Series A Round Funding
